Global segment ranking · Healthtech › Access to care

The world’s most valuable telemedicine companies

Virtual-first care providers whose main activity is online consultations and virtual primary or specialty care, from generalist telehealth to digital physiotherapy and obesity care. Ranked worldwide by AI-estimated valuation. The market sets the value; our AI estimates it.

Edition 0 (beta) · Published September 29, 2026 Twice a yearNext edition: January 1, 2027· Claude · multi-AI consensus in a future edition· Published method· Order never changed by a human

Key metrics for this segment: patients / members, revenue. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.

Not in this segment. Appointment booking, online pharmacy, mental health (including teletherapy), women's health (including women's telehealth) and connected devices each have their own segment. A company appears in one segment only. Method

The segment at a glance

10companies ranked

3companies on the radar

5countries in the ranking

6listed benchmarks

Sources: TechCrunch, MobiHealthNews, Fierce Healthcare, Healthcare Dive, Bloomberg Tax, Sacra, Forge Global, Caproasia, ChinaVenture, DealStreetAsia, Stock Analysis, Halle Tecco, company announcements. Intention counters will be shown above a threshold of amount and number of Backers.

Rankings by region

Filter the ranking and the Radar. Ranks stay worldwide.

Global ranking · Telemedicine

Top 10 Radar Challengers

First edition: no movements yet.

World · 10 ranked companies

#	Company	Last round · Key metrics	Estimated valuation (AI, order of magnitude)	Confidence	Invest
1	RoUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Equity round · USD 150M · Feb 2022Patients / members: n/d · Revenue ~$598M (estimate) · 2024	Last known equity round: Equity round · USD 150M · Feb 2022 (led by ShawSpring Partners, with General Catalyst, FirstMark Capital, TQ Ventures) Published valuation: USD 7bn (Feb 2022) Confidence index: MediumMethod	Partial sources	Declare an intent
2	Sword HealthUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Equity round · USD 40M · Jun 2025Patients / members: n/d · Revenue $240M annual run rate · Jun 2025	Last known equity round: Equity round · USD 40M · Jun 2025 (led by General Catalyst) Published valuation: USD 4bn (Jun 2025) Confidence index: HighMethod	Solid sources	Declare an intent
3	TranscarentUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Preferred equity · amount not disclosed (preferred stock financing the Accolade deal) · Jan 202520M+ members; 1,700+ employer and health plan clients · Revenue: n/d · 2025	Last known equity round: Preferred equity · amount not disclosed (preferred stock financing the Accolade deal) · Jan 2025 (led by General Catalyst and 62 Ventures) Published valuation: USD 2.2bn (May 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
4	eMedUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series A · USD 200M · Mar 2026Key metrics not disclosed	Last known equity round: Series A · USD 200M · Mar 2026 (led by Aon Consulting, with Tom Brady, Joe Lonsdale, Antonio Gracias) Published valuation: over USD 2B (Mar 2026) Confidence index: HighMethod	Solid sources	Declare an intent
5	Included HealthUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series E (Grand Rounds) · USD 103M · Sep 2020Tens of millions of members; 300+ employer and health plan clients · Revenue: n/d · 2026	Last known equity round: Series E (Grand Rounds) · USD 103M · Sep 2020 (led by The Carlyle Group) Published valuation: USD 1.13B (Grand Rounds, before merger with Doctor On Demand) (Sep 2020) Confidence index: LowMethod	Weak sources	Declare an intent
6	WeDoctorChina · Asia-PacificSources: 1 · 2Is this your company? Report an error	Equity round · USD 163M · Sep 2022240M+ registered users (2025) · Revenue RMB 1.86B (~$260M) (FY2023)	Last known equity round: Equity round · USD 163M · Sep 2022 (Tencent-backed; investors include HongShan, Hermitage Capital, CICCFH, Qiming, AIA) Published valuation: USD 6.7bn (2022) Confidence index: LowMethod	Weak sources	Declare an intent
7	Virta HealthUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series E · USD 133M · Apr 2021Patients / members: n/d · Revenue ~$158M annualized · Aug 2025	Last known equity round: Series E · USD 133M · Apr 2021 (led by Tiger Global) Published valuation: USD 2bn (Apr 2021) Confidence index: MediumMethod	Partial sources	Declare an intent
8	Kry (Livi)Sweden · EuropeSources: 1 · 2Is this your company? Report an error	Series D follow-on · USD 160M (equity and debt) · 202212M+ consultations a year · Revenue SEK 2.5B (~$240M) · FY2024	Last known equity round: Series D follow-on · USD 160M (equity and debt) · 2022 (led by Teachers' Venture Growth and P Capital Partners) Published valuation: USD 2bn (Apr 2021) Confidence index: MediumMethod	Partial sources	Declare an intent
9	HalodocIndonesia · Asia-PacificSources: 1 · 2Is this your company? Report an error	Series D · USD 100M (USD 135M Series D in total per Novo Holdings) · Jul 202320M+ monthly active users · Revenue: n/d · 2023	Last known equity round: Series D · USD 100M (USD 135M Series D in total per Novo Holdings) · Jul 2023 (led by Astra International, with Openspace and Novo Holdings) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
10	Doctor AnywhereSingapore · Asia-PacificSources: 1 · 2Is this your company? Report an error	Series C · USD 58.7M (USD 65.7M with extension) · Aug 2021Key metrics not disclosed	Last known equity round: Series C · USD 58.7M (USD 65.7M with extension) · Aug 2021 (led by Asia Partners and Novo Holdings) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent

Ranking in descending order of AI-estimated valuation, based on public information, following a published method, with no human intervention on the order. Valuation ranges are indicative editorial estimates: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Edition 0: produced by Claude (Anthropic); a consensus of several AI models will apply in a future edition. Eligibility: at least $1M raised including one equity round, non-listed company, main activity in this segment (virtual-first consultations and virtual primary and specialty care). Country shown is the country of main operations. Request a correction

Get every new edition

New entries, exits and movements, twice a year.

One e-mail per edition. One-click unsubscribe. No data passed on to third parties.

How to read this ranking

Rank

Companies are ranked by AI-estimated valuation, highest first. The market sets the value; our AI estimates it.

Range

An order of magnitude, never a figure.

Hundreds of k$
Millions $
Tens of M$
Hundreds of M$
Unicorn
Decacorn

Confidence

High: recent published valuation or round (under 24 months).
Medium: older data.
Low: single or unconfirmed source.

Full method →

Invest in telemedicine, together

Uback aggregates investment intentions from business angels, family offices, corporates and sector specialists worldwide. Every ranked company already has professional investors on its cap table, who have negotiated a shareholders’ agreement: you don’t start from a blank page.

Strength in numbers

Alone, a small ticket opens no doors. Together, Backers carry weight.

Declare an intention

On a company or a sector, with a ticket range. Paid, to show you are serious; transferable as long as it has not been converted.

Critical mass is reached

When the number of Backers and the total of their intentions cross a threshold, the licensed partner contacts the company and presents this demand.

The licensed partner structures

If the company’s expectations and the Backers’ converge, the partner builds a transaction and presents it directly to the Backers concerned.

Closing

Capital raise or sale of existing shares: small tickets are pooled in a common vehicle set up by the licensed partner. Each Backer decides whether to take part.

Uback does not advise, does not negotiate, collects nothing. Each transaction is run by the licensed partner of the company’s country, under the law that governs its shares.

Get notified when intentions open What happens after my declaration? Intention declarations open once the licensed partner signs · price per ticket band · valid 12 months · transferable credit

Challengers

A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.

Sponsored space · no Challenger listed yet

Radar · known eligible companies, not ranked

Sorted by date of last round, with no judgement and no AI call.

Altibbi · Jordan · Middle East & North AfricaMar 2023 · USD 44M
Found · United States · North America2022 · USD 100M
Medadom · France · Europe2020 · USD 47M

Listed benchmarks

Not ranked: no intention is possible on a listed company.

Hims & Hers Health · United StatesNYSE · HIMS
Teladoc Health · United StatesNYSE · TDOC
Hinge Health · United StatesNYSE · HNGE
Omada Health · United StatesNASDAQ · OMDA
American Well (Amwell) · United StatesNYSE · AMWL
Ping An Good Doctor (Ping An Healthcare and Technology) · ChinaHKEX · 1833

Sources and method for this segment

Calendar. Global segment rankings are published twice a year. Next edition: January 1, 2027.

Eligibility. At least $1M raised including one equity round, non-listed company, main activity in this segment (virtual-first consultations and virtual primary and specialty care). A company appears in one segment only.

Sources. TechCrunch, MobiHealthNews, Fierce Healthcare, Healthcare Dive, Bloomberg Tax, Sacra, Forge Global, Caproasia, ChinaVenture, DealStreetAsia, Stock Analysis, Halle Tecco, company announcements.

Method and rules, common to all rankings →